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Evidence Based Medicine
My patient just had a transient ischaemic attack. Can I predict his
risk for stroke? Is stroke inevitable or preventable?
Maria Khan,1 Ayeesha Kamran Kamal2
Fellow International Cerebrovascular Translational Clinical Research Training Program, Stroke Service,1
Director Stroke Service and Vascular Fellowship Program,2 Aga Khan University Hospital , Karachi, Pakistan.

Transient Ischaemic Attack:
Transient Ischaemic attack or TIA has traditionally
been defined as a discrete neurological deficit lasting for < 24
hours. The new definition of a TIA is that of a brief
neurological dysfunction caused by focal brain or retinal
ischaemia and lasting for < 1 hour without signs of infarction
on brain MRI. Hence, a tissue based rather than a time based
definition is being proposed.

What is the risk of recurrent TIA after an
index TIA? What is the risk of stroke?
TIA puts a patient at a higher risk of subsequent stroke
with a 2-day risk being quoted at 5-6%, 90-day stroke risk
estimated at 10.5% and a 6-month stroke risk estimated to be
17%. It is important to realize that a subset of patients is at a
higher risk of recurrent TIA as opposed to a subset which is
at higher risk for a subsequent stroke. Those older than 60
years are at higher risk for both TIA and stroke. Additionally
those with Diabetes, those with motor weakness and those
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with speech impairment are at a higher risk of subsequent
stroke and therefore need to be managed more aggressively.

Risk stratification after a TIA — The ABCD-2
score:
ABCD 2 score is now a well recognized prognostic score
for predicting individuals at high risk for stroke. BP in excess of
140/90, unilateral weakness and duration of symptoms >60 min
are the strongest risk factors for recurrent events.
Based on this score, low risk is defined as a score of
less than 4 (stroke risk 1·0% at 2 days, 1·2% at 7 days, and
3·1% at 90 days), moderate risk is a score of 4 or 5 (stroke
risk 4·1% at 2 days, 5·9% at 7 days, and 9·8% at 90 days), and
high risk is a score of greater than 5 (stroke risk 8·1% at 2
days, 11·7% at 7 days, and 17·8% at 90 days).

What investigations are warranted once a TIA
is diagnosed?
Recommended acute approaches in patients with TIA
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Table: Validated Scale for Predicted 2-day stroke risk after TIA.
Factor
Age
Blood Pressure
Clinical Features
Duration
Diabetes
Total score

Description

Points

> 60 years
SBP>140 and DBP>90 mm HG
Unilateral weakness
Speech impairment w/o weakness
> 60 min
10-59 min
Self reported history

1
1
2
1
2
1
1
9

Ref: Johnston et al.4

include, brain imaging, preferably MRI with MR
angiography, ECG to rule out rhythm abnormality and
echocardiography to exclude cardio-embolism and carotid
imaging for significant stenosis. Expedited testing based on
ABCD2 score appears to be the way for high risk patients.

What therapy is indicated after a TIA?
For TIAs of cardioembolic origin, warfarin is
irrefutably the only therapeutic option at present. For noncardioembolic TIAs, there is very little direct evidence to
guide management after and index TIA. The available
evidence comes from two recent trials, FASTER and EARLY.
FASTER was a pilot trial designed to test early
aggressive use of dual anti-platelets aspirin and clopidogrel
after TIA or minor stroke. It showed that the early high risk
can be decreased with the combination without the excess
risk of haemorrhage.
EARLY is the other trial that investigated the benefit
of combination anti-platelets (aspirin and dipyridamole in
this case) when started within 24 hour of symptom onset as
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opposed to starting at 7 days. The trial showed that it is just
as safe and efficacious to start early than late with no
significant differences in terms of disability. In total, these
early phase trials suggest that early dual anti-platelet therapy
may be safe after a TIA.

Conclusion
All patients presenting with TIA must be risk stratified
using the ABCD-2 score and investigated promptly. It may be
safe to start dual anti-platelets for the initial one week. Future
trials in Pakistani patients to validate the TIA scores locally
would be useful.
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